{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:26:07Z","timestamp":1726273567816},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,12]]},"DOI":"10.7759\/cureus.69301","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:21:27Z","timestamp":1726208487000},"source":"Crossref","is-referenced-by-count":0,"title":["A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report"],"prefix":"10.7759","author":[{"given":"Raluca Ioana","family":"Mihaila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelina Silvana","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Luminita","family":"Zob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Lucia","family":"Stanculeanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem S","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, et al.. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017, 111:176-81. 10.1016\/j.lungcan.2017.07.024","journal-title":"Lung Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients","volume":"112","author":"Ferrucci PF","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A, et al.. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015, 112:1904-10. 10.1038\/bjc.2015.180","journal-title":"Br J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000748","article-title":"C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting","volume":"31","author":"Lauwyck J","year":"2021","unstructured":"Lauwyck J, Beckw\u00e9e A, Santens A, et al.. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Res. 2021, 31:371-7. 10.1097\/CMR.0000000000000748","journal-title":"Melanoma Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino AS","year":"2020","unstructured":"Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020, 8:e000842. 10.1136\/jitc-2020-000842","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou J","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, et al.. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017, 5:480-92. 10.1158\/2326-6066","journal-title":"Cancer Immunol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman AM","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, et al.. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017, 16:2598-608. 10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol Cancer Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee JH","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, et al.. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017, 28:1130-6. 10.1093\/annonc\/mdx026","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray ES","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, et al.. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015, 6:42008-18. 10.18632\/oncotarget.5788","journal-title":"Oncotarget"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara DR","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, et al.. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018, 24:1441-8. 10.1038\/s41591-018-0134-3","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou V","year":"2020","unstructured":"Anagnostou V, Niknafs N, Marrone K, et al.. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer. 2020, 1:99-111. 10.1038\/s43018-019-0008-8","journal-title":"Nat Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study","volume":"28","author":"Cabel L","year":"2017","unstructured":"Cabel L, Riva F, Servois V, et al.. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study. Ann Oncol. 2017, 28:1996-2001. 10.1093\/annonc\/mdx212","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025318","article-title":"Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: A meta-analysis","volume":"100","author":"Xu J","year":"2021","unstructured":"Xu J, Zhao J, Wang J, Sun C, Zhu X. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: A meta-analysis. Medicine (Baltimore). 2021, 100:e25318. 10.1097\/MD.0000000000025318","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040450","article-title":"Blockade of lactate dehydrogenase-A (LDH-A) improves efficacy of anti-programmed cell death-1 (PD-1) therapy in melanoma","volume":"11","author":"Daneshmandi S","year":"2019","unstructured":"Daneshmandi S, Wegiel B, Seth P. Blockade of lactate dehydrogenase-A (LDH-A) improves efficacy of anti-programmed cell death-1 (PD-1) therapy in melanoma. Cancers (Basel). 2019, 11:450. 10.3390\/cancers11040450","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1237643","article-title":"Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1","volume":"13","author":"Janka EA","year":"2023","unstructured":"Janka EA, V\u00e1nyai B, Szab\u00f3 IL, et al.. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1. Front Oncol. 2023, 13:1237643. 10.3389\/fonc.2023.1237643","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.748674","article-title":"The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: A systematic review and meta-analysis","volume":"13","author":"Ning B","year":"2022","unstructured":"Ning B, Liu Y, Wang M, Li Y, Xu T, Wei Y. The predictive value of tumor mutation burden on clinical efficacy of immune checkpoint inhibitors in melanoma: A systematic review and meta-analysis. Front Pharmacol. 2022, 13:748674. 10.3389\/fphar.2022.748674","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0983","article-title":"TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma","volume":"9","author":"Hodi FS","year":"2021","unstructured":"Hodi FS, Wolchok JD, Schadendorf D, et al.. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol Res. 2021, 9:1202-13. 10.1158\/2326-6066.CIR-20-0983","journal-title":"Cancer Immunol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.53697","article-title":"Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma","volume":"12","author":"Zhang C","year":"2021","unstructured":"Zhang C, Dang D, Liu C, Wang Y, Cong X. Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma. J Cancer. 2021, 12:2440-9. 10.7150\/jca.53697","journal-title":"J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2251","article-title":"Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy","volume":"26","author":"Marsavela G","year":"2020","unstructured":"Marsavela G, Lee J, Calapre L, et al.. Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy. Clin Cancer Res. 2020, 26:5926-33. 10.1158\/1078-0432.CCR-20-2251","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113476","article-title":"PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma","volume":"198","author":"Ellebaek E","year":"2024","unstructured":"Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M, Svane IM. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024, 198:113476. 10.1016\/j.ejca.2023.113476","journal-title":"Eur J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher VE","year":"2019","unstructured":"Maher VE, Fernandes LL, Weinstock C, et al.. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019, 37:2730-7. 10.1200\/JCO.19.00318","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/292040-a-complete-response-in-a-metastatic-melanoma-patient-after-a-single-dose-of-dual-checkpoint-inhibitors-blockade-could-be-predictable-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:21:30Z","timestamp":1726208490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/292040-a-complete-response-in-a-metastatic-melanoma-patient-after-a-single-dose-of-dual-checkpoint-inhibitors-blockade-could-be-predictable-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.69301","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}